These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38589248)

  • 1. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.
    Ouyang W; Jin SW; Xu N; Liu WY; Zhao H; Zhang L; Kang L; Tao Y; Liu Y; Wang Y; Wang J; Liu F; Yu L; Liu Z; Mi JQ
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38589248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
    Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
    J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
    Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
    Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
    Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

  • 10. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
    Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
    Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
    Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
    [No Abstract]   [Full Text] [Related]  

  • 14. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.
    Buonato JM; Edwards JP; Zaritskaya L; Witter AR; Gupta A; LaFleur DW; Tice DA; Richman LK; Hilbert DM
    Mol Cancer Ther; 2022 Jul; 21(7):1171-1183. PubMed ID: 35737298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
    Gagelmann N; Ayuk F; Atanackovic D; Kröger N
    Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
    Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 20. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
    Xu J; Ming X; Wang C; Xu B; Xiao Y
    Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.